By abhat@reaganud… on
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?term=Arcturus&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=c&recrs=k&age_v=&gndr=&type=&rslt=
COVID-19 Information

LUNAR-COV19 - Arcturus is combining its self-replicating mRNA STARR™ Technology with their LUNAR® RNA medicine delivery technology to developing a prophylactic vaccine against COVID-19. The combination of these two technologies results in (1) an mRNA vaccine that can be produced more rapidly than conventional adjuvanted protein based vaccine; (2) a significant reduction in the mRNA dose required to elicit a protective immune response; and (3) an increase in the duration of antigen expression potentially yielding protection from COVID-19 with a single dose.

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology

Stage
Pre-clinical
Company Type
Vaccine